CYP与NAT2遗传关联对新疆维吾尔族、汉族抗结核药物诱导肝损害的易感性研究

本项目将对新疆汉族、维吾尔族健康人群、肺结核患者和肺结核患者服用抗结核药物诱导肝损害患者的CYP2E1、NAT2基因多态性进行测定。将均具有遗传多态性的药物代谢酶CYP2E1和NAT2相联系，与在体质和遗传构成上有明显差异的种族人群相结合，采用健康人群与肺结核患者、肺结核患者与肺结核患者服用抗结核药物诱导肝损害患者的病例对照。探讨两个民族人群间CYP2E1、NAT2基因多态性存在遗传差异； CYP2E1和NAT2基因多态性及关联与结核病的相关性；两个民族人群CYP2E1和NAT2酶活性的关联对抗结核药物诱导肝损害发生的易感因素。揭示不同种族人群和个体因其遗传多态性的关联而导致在临床表现的多样性及对药物反应的差异，有助于弄清抗结核药物诱导肝损害的发病机制。

This research project will study polymorphism of CYP2E1 and NAT2 genes in healthy population, lung tuberculosis patients and lung tuberculosis patients taking antituberculosis drug induced hepatic harm of Uigur and Han in Xinjiang. With drug metabolism of genetic polymorphism CYP2E1 and NAT2 genes connect to significant difference of body constitution and genetic structure of ethnic groups, using case control in healthy population, lung tuberculosis patients and lung tuberculosis patients taking antituberculosis drug induced hepatic harm for research. It will explore CYP2E1 and NAT2 genes polymorphism on genetic difference in two ethnic groups. Study on CYP2E1 and NAT2 gene polymorphism associated with lung tuberculosis and study on susceptivity of CYP2E1 and NAT2 genes in two ethnic groups related to antituberculosis drug induced hepatic harm. This research will reveal different ethnic groups and individual with genetic polymorphism correlation result in variety of clinic situation to the different drug response, this research will understand pathogenesis for antituberculosis drug induced hepatic harm.